Tidutamab, an emerging antibody, represents driving considerable attention in the field of cancer treatment. Its journey began with inhibiting a latent associated protein marker, a critical component considered to https://adreaghdf734162.blognody.com/50079177/tidutamab-the-deep-dive-into-its-development-and-potential